Eur Urol Focus:单侧低风险前列腺癌的血管靶向光动力治疗

2021-03-11 AlexYang MedSci原创

血管靶向光动力疗法(VTP)是一种批准的单侧低风险前列腺癌(PCa)的治疗选择。

血管靶向光动力疗法(VTP)是一种批准的单侧低风险前列腺癌(PCa)的治疗选择。

最近,有研究人员报告了VTP治疗患者的初步经验。研究人员将短期功能和肿瘤学结果与接受根治性前列腺切除术(RP)治疗单侧低风险PCa的连续患者队列进行了比较。

研究人员对接受VTP(n=41)和RP(n=49)的单侧低风险PCa患者进行了评估。结果表明,在VTP后的12个月和24个月对照活检中(n=22),45%的VTP患者没有显示PCa的证据。27%的患者中检测到低危和中危PCa。RP患者中无一例PCa复发。在VTP和RP患者中,分别有71%和30%的患者保留了勃起功能。在VTP患者中,88%的患者没有出现膀胱出口梗阻。在RP患者中,分别有96%和4%的患者每天使用零到一个和两个或更多的护垫。数据采集是在临床试验之外进行的。同时,必须考虑到短期随访和少量的复检患者。

VTP之后的肿瘤复发(A)和肿瘤进展(B)

最后,研究人员指出,VTP是单侧低风险PCa的一种有前途的治疗方案,在现实世界中比RP的并发症更少。然而,在这个低风险PCa队列中,VTP后的复发和进展是常见的,必须与希望进行VTP而不是积极监测的患者进行认真讨论,且需要采用多参数磁共振成像和对照活检的严格监测。

原始出处:

Luka Flegar , Bj?rn Buerk , Rick Proschmann et al. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy. Eur Urol Focus. Feb 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1719561, encodeId=b1441e195613e, content=<a href='/topic/show?id=404928e34f6' target=_blank style='color:#2F92EE;'>#光动力治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28734, encryptionId=404928e34f6, topicName=光动力治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c432763729, createdName=wshxjq, createdTime=Fri Nov 26 09:54:13 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951224, encodeId=b5e495122450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 17:32:30 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546333, encodeId=4eb915463336b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Sat Mar 13 04:54:13 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040976, encodeId=34cb10409e6c5, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 11 16:54:13 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1719561, encodeId=b1441e195613e, content=<a href='/topic/show?id=404928e34f6' target=_blank style='color:#2F92EE;'>#光动力治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28734, encryptionId=404928e34f6, topicName=光动力治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c432763729, createdName=wshxjq, createdTime=Fri Nov 26 09:54:13 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951224, encodeId=b5e495122450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 17:32:30 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546333, encodeId=4eb915463336b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Sat Mar 13 04:54:13 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040976, encodeId=34cb10409e6c5, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 11 16:54:13 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
    2021-03-25 ms9000000127731620

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1719561, encodeId=b1441e195613e, content=<a href='/topic/show?id=404928e34f6' target=_blank style='color:#2F92EE;'>#光动力治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28734, encryptionId=404928e34f6, topicName=光动力治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c432763729, createdName=wshxjq, createdTime=Fri Nov 26 09:54:13 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951224, encodeId=b5e495122450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 17:32:30 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546333, encodeId=4eb915463336b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Sat Mar 13 04:54:13 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040976, encodeId=34cb10409e6c5, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 11 16:54:13 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1719561, encodeId=b1441e195613e, content=<a href='/topic/show?id=404928e34f6' target=_blank style='color:#2F92EE;'>#光动力治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28734, encryptionId=404928e34f6, topicName=光动力治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c432763729, createdName=wshxjq, createdTime=Fri Nov 26 09:54:13 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951224, encodeId=b5e495122450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 17:32:30 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546333, encodeId=4eb915463336b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Sat Mar 13 04:54:13 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040976, encodeId=34cb10409e6c5, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 11 16:54:13 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
    2021-03-11 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

段医生的亲身经历文章:患者大出血,血管被扯断,我们怎么救

作为一名医生,几十年奋战在临床一线,终日在刀尖上跳舞,我以为自己早已看惯生死一线的惊心动魄,但那天的境遇还是深深震撼了我,触动了生命源头的那种恐惧、渴望,激发了奋力一搏的欲望。那是一个平凡的日子,我在一家地区级三甲医院做一个常诊手术,这是工作计划中的一个病例,巨大肝癌。我像往常一样迈着轻松的步子和主任们一起走进手术室,按照行程计划,我 09:00 准时开刀,到中午 12:00-13:00 左右

JACC:马拉松训练可以逆转年龄引起的血管硬化

年龄会增加主动脉的硬度,从而增加健康人群心血管疾病的风险。本研究的目的旨在评估第一次的马拉松训练是否能逆转年龄带来的主动脉硬度变化。本研究对未受过锻炼的健康人群进行了6个月的马拉松训练,训练前和马拉松后2周的评估包括中心(主动脉)血压和主动脉硬度。最终,共纳入分析了138名第一次参加马拉松的对象(21-69岁,男性占49%),平均每周的训练计划为6-13英里。在基线水平,10年的老化时间分别与升主

Stroke:血管再通降低脑水肿的风险,增加脑实质出血的风险

急性缺血性卒中后脑水肿(Cerebral edema,CED)会恶化患者的预后,如果严重甚至会引起威胁生命的脑组织移位。

Lancet:儿童新冠肺炎症状较轻或与血管有关

近日,《柳叶刀》发表的一项研究表明,答案可能隐藏在儿童健康的血管中。

Hypertension:血管紧张素转换酶抑制剂和他汀类药物对1型糖尿病青少年血管的效应

ACE抑制剂可改善高危青少年的血管内皮功能。这种干预在早年的长期保护作用尚未明确。

Neurology:Erenumab预防偏头痛的血管安全性

由此可见,用Erenumab选择性阻断经典降钙素基因相关肽受体进行偏头痛预防12周内的血管安全性可与安慰剂媲美,并且随着时间的推移,病例没有增加。需要进一步研究来验证Erenumab对偏头痛患者的长期安全性。